Provider	American Society of Hematology
Accreditation Type	Physicians—maximum of .50 AMA PRA Category 1 Credit(s)™ Nurses— 0.50 contact hours of nursing continuing professional development credit
Accreditor	The American Society of Hematology and The France Foundation
Release Date	November 10, 2023
Expiration Date	November 10, 2026
Estimated Time to Complete Activity	30 minutes

Description

This activity provides education to assist clinicians in improving care of patients with paroxysmal nocturnal hemoglobinuria (PNH) through a greater understanding of pathophysiologic mechanisms of PNH, the limitations of current therapies and their impact on patients’ QoL and outcomes, the latest data on emerging treatment options, and how these treatments may impact clinical care.

Target Audience

This educational activity is intended for hematologists, hematologists/oncologists, nurse practitioners, physician associates, and other members of the health care team who are involved in the care of patients with paroxysmal nocturnal hemoglobinuria (PNH).

Learning Objectives

Upon completion of this course, the learners should be able to:

• Identify how current and emerging therapies target the complement pathway in patients with PNH
• Outline the safety and efficacy of new and emerging therapies for PNH
• Associate potential clinical impact of emerging therapies in addressing limitations of current treatments in patients with PNH